Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) Demonstrating Slowed Disease Progression and Improved Function
Primary endpoint, change in DUX4-driven gene expression which was included as an experimental biomarker, was not met
